Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 8NET 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Dermatologic 1CNS 1Breast 1

Conditions

Pancreatic Neoplasms 51Colorectal Neoplasms 44Carcinoma, Hepatocellular 36Rectal Neoplasms 26Lung Neoplasms 23Colonic Neoplasms 22Neoplasm Metastasis 18Esophageal Neoplasms 18Cholangiocarcinoma 15Breast Neoplasms 13Stomach Neoplasms 12Glioma 11Ovarian Neoplasms 10Melanoma 10Carcinoma, Non-Small-Cell Lung 10Carcinoma, Renal Cell 9Anus Neoplasms 9Sarcoma 8Uterine Cervical Neoplasms 7Prostatic Neoplasms 7Medulloblastoma 7Lymphoma, Non-Hodgkin 7Ependymoma 7Carcinoma, Transitional Cell 7Brain Neoplasms 7Adenocarcinoma Of Esophagus 7Wilms Tumor 6Rhabdomyosarcoma 6Rhabdoid Tumor 6Neuroectodermal Tumors, Primitive, Peripheral 6

Interventions

pembrolizumab 3spartalizumab 2trametinib 1tislelizumab 1palbociclib 1nazartinib 1milademetan 1enzalutamide 1devimistat 1dehydroftorafur 1canakinumab 1binimetinib 1bemarituzumab 1aldesleukin 1Specimen Handling 1Pentostatin 1Midazolam 1Methods 1Magnetic Resonance Spectroscopy 1Letrozole 1Interleukin-2 1IFL protocol 1Hydroxychloroquine 1Gemcitabine 1Fulvestrant 1Fluorouracil 1Early Intervention, Educational 1Cyclophosphamide 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma of Lung × Magnetic Resonance Spectroscopy × Gastrointestinal × Clear all
NCT05733000 2023-03-10

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Northwestern University

Phase 2 Recruiting
94 enrolled
GastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma of Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡